Drugs / ALG-000184
ALG-000184
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07342881 | Feb → Jun 2026 overdue | chronic hepatitis B virus infection | Aligos Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT07342868 | Jan → Apr 2026 overdue | chronic hepatitis B virus infection | Aligos Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT06672900 | Jan → Jul 2025 overdue | — | Aligos Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04536337 | Oct 2020 → Jun 2025 | chronic hepatitis B virus infection | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06963710 | Jul 2025 → Mar 2027 expected | chronic hepatitis B virus infection | Aligos Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALG-000184 | “Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium” NCT07342868 ↗ |
| Known as | Pevifoscorvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07342881 ↗ |
| Known as | pevifoscorvir sodium | “Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium” NCT07342868 ↗2“ALG-000184 (pevifoscorvir sodium) is a prodrug of the class-E” PMID 41554267 ↗ Jan 2026 “Pevifoscorvir Sodium (ALG-000184)” NCT07342881 ↗ |
| Action | Inhibit | “ALG-000184 is a prodrug that is converted to ALG-001075, a Class E CAM that inhibits HBV replication through two mechanisms:” NCT04536337 ↗ |
| Modality | Other / unclassified | “ALG-000184 is a prodrug that is converted to ALG-001075, a Class E CAM” NCT04536337 ↗ |
| Route | Oral | “Eligible patients were randomly assigned (4:1) to receive 28 days of oral ALG-000184 (10 mg, 50 mg, 100 mg, or 300 mg) or matching placebo once per day.” PMID 41554267 ↗ Jan 2026 |